News | March 01, 2024
Pfizer Oncology hosts innovation day
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Subscribe To Our Newsletter & Stay Updated
